Pharmacokinetic and Exposure–Response Analyses of Leuprolide Following Administration of Leuprolide Acetate 3-Month Depot Formulations to Children with Central Precocious Puberty

详细信息    查看全文

• 作者：Nael M. Mostafa (1)
  Balakrishna Hosmane (2)
  Lois M. Larsen (1)
  Kristof Chwalisz (1)
  Yi-Lin Chiu (1)
  Rajendra S. Pradhan (1)
  
• 刊名：Clinical Drug Investigation
• 出版年：2014
• 出版时间：July 2014
• 年：2014
• 卷：34
• 期：7
• 页码：441-448
• 全文大小：
• 参考文献：1. Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet. 2002;41(7):485-04. CrossRef
  2. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert, ESPE-LWPE S GnRH Analogs Consensus Conference Group, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):752-2. CrossRef
  3. LUPRON DEPOT-PED^? [package insert]. North Chicago, IL: Abbott Laboratories.
  4. Lee PA, Neely EK, Fuqua J, Yang D, Larsen L, Mattia-Goldberg C, Chwalisz K. Efficacy of leuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study. Int J Pediatr Endocrinol. 2011;2011(1):7.
  5. Lee PA, Klein K, Mauras N, Neely EK, Bloch CA, Larsen L, Mattia-Goldberg C, Chwalisz K. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab. 2012;97(5):1572-0. CrossRef
  6. Garibaldi LR, Aceto T Jr, Weber C, Pang S. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test. J Clin Endocrinol Metab. 1993;76(4):851-.
  7. Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N. Three-month sustained-release triptorelin (11.25?mg) in the treatment of central precocious puberty. Eur J Endocrinol. 2006;154(1):119-4.
  8. Carel JC, Léger J. Clinical practice. Precocious puberty. N Engl J Med. 2008;358(22):2366-7. CrossRef
  9. Sennello LT, Finley RA, Chu SY, et al. Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. J Pharm Sci. 1986;75(2):158-0. CrossRef
  10. Jocham D. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol Int. 1998;60(Suppl 2):18-4 discussion 35. CrossRef
  11. Mostafa NM, Chwalisz K, Larsen L, Mattia-Goldberg C, Spitz A, Pradhan RS. Evaluation of the pharmacokinetics and pharmacodynamics of two leuprolide acetate 45?mg 6-month depot formulations in patients with prostate cancer. Clin Pharmacol Drug Dev. 2014;. doi:10.1002/cpdd.112 .
  12. Carel JC, Lahlou N, et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25?mg). J Clin Endocrinol Metab. 2002;87(9):4111-. CrossRef
  
• 作者单位：Nael M. Mostafa (1)
  Balakrishna Hosmane (2)
  Lois M. Larsen (1)
  Kristof Chwalisz (1)
  Yi-Lin Chiu (1)
  Rajendra S. Pradhan (1)
  
  1. Research and Development, AbbVie Inc., One N. Waukegan Road, North Chicago, IL, 60064, USA
  2. Division of Statistics, Northern Illinois University, DeKalb, IL, USA
  
• ISSN：1179-1918

文摘

Background and Objective A pharmacokinetic substudy was conducted within a phase 3 clinical trial that evaluated the efficacy and safety of two leuprolide acetate 3-month depot formulations in children with central precocious puberty (CPP), where the pharmacokinetics of leuprolide and the exposure–response relationship between leuprolide concentration and the probability of luteinizing hormone (LH) suppression were assessed. Methods Children diagnosed with CPP (N?=?42 in each dosing cohort), who were treatment na?ve or previously treated, received a?total of two intramuscular injections of either leuprolide acetate depot 11.25 or 30?mg formulations administered 3?months apart. Serial blood samples were collected for leuprolide concentration determination in a subset of subjects (N?=?24 in each cohort). One-way analysis of covariance was used to assess dose proportionality. The probability of LH suppression (peak-stimulated LH concentrations <4?mIU/mL) exposure–response relationship was modelled using repeated measures logistic regression. The predicted probability of LH suppression and the corresponding 95?% confidence interval at the mean leuprolide concentration of each dose group and at each time of measurement were computed. Results Mean leuprolide concentrations between weeks 4 and 12 for 11.25 and 30?mg doses were relatively constant and dose proportional, with no accumulation of leuprolide upon repeated administration. Body weight and age were not found to be significant covariates on leuprolide pharmacokinetics. Higher leuprolide concentrations were associated with higher probability of LH suppression and both doses provided LH suppression levels <4?mIU/mL. Conclusion Leuprolide pharmacokinetics were characterized for 11.25 and 30?mg 3-month depot injections. An exposure–response model was developed to link leuprolide concentrations and probability of peak-stimulated LH suppression.